Jump to Navigation

Facebook Connect

User login

Lipid Insights: Lysosomal Acid Lipase (LAL) Deficiency

Lipid Insights: Lysosomal Acid Lipase (LAL) Deficiency


Schedule: On Demand (The original live program aired on Monday December 9, 2013)

Program Overview:

The Lipid Insights Virtual Journal Club, a 60-minute CME Webcast with a live Q&A session, is designed to offer members and others an interactive way to discuss important clinical trial updates. This program will discuss LAL Deficiency which belongs to the Lysosomal Storage Disorder disease family. Join Dr. Rader as he discusses how to identify and manage LAL Deficiency.

Moderator:
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA

President, Northeast Lipid Association
NYU Medical School
New York, NY

Speaker:
Daniel J. Rader, MD, FNLA

University of Pennsylvania
Philadelphia, PA

Technical Support

This program requires a current version of ONE of the following web browsers, with JavaScript enabled:

  • Google Chrome
  • Firefox 5.0 or greater
  • Safari
  • Internet Explorer 8.0 or greater

This NLA Lipid Insights Archive Program is Mobile Device friendly. If you experience difficulty viewing the video portion of this program, please contact us.

The handouts portion of this program requires the Adobe Acrobat Reader or a similar PDF program. You probably already have it; but if you cannot view the handouts, you can obtain the Adobe Acrobat Reader here.

If you require assistance to view/hear this program, please contact us.

4.666665
Average: 4.7 (3 votes)

Education Information

This program, though not accredited in its archived form, is targeted towards specific content areas and learning objectives.



Content Domain
This activity falls under the following content domain(s):

  • 1.1 Lipoprotein Composition and Structure

Learning Objectives
This activity teaches to the following learning objective(s):

  1. Define Lysosomal Acid Lipase (LAL) deficiency and describe the prevalence and associated risk, in order to increase awareness and understanding of the disease
  2. Evaluate the clinical effects, safety and efficacy data for current and new treatment options for patients with LAL deficiency



by Dr. Radut.